Eledon Pharmaceuticals マネジメント

マネジメント基準チェック /24

Eledon Pharmaceuticalsの CEO はDA Grosで、 Sep2020年に任命され、の在任期間は 4.17年です。の年間総報酬は$ 2.55Mで、 21.9%給与と78.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.015%を直接所有しており、その価値は€ 36.21K 。経営陣と取締役会の平均在任期間はそれぞれ3.6年と5.9年です。

主要情報

DA Gros

最高経営責任者

US$2.6m

報酬総額

CEO給与比率	21.9%
CEO在任期間	4.2yrs
CEOの所有権	0.02%
経営陣の平均在職期間	3.6yrs
取締役会の平均在任期間	5.9yrs

経営陣の近況

Recent updates

CEO報酬分析

Eledon Pharmaceuticals の収益と比較して、DA Gros の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$25m
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$3m	US$559k	-US$117m
Sep 30 2023	n/a	n/a	-US$145m
Jun 30 2023	n/a	n/a	-US$145m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$1m	US$533k	-US$88m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$748k	US$504k	-US$35m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$7m	US$150k	-US$23m

報酬と市場: DAの総報酬 ($USD 2.55M ) は、 German市場 ($USD 787.21K ) の同規模の企業の平均を上回っています。

報酬と収益: DAの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

DA Gros (52 yo)

4.2yrs

在職期間

US$2,553,153

報酬

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
David-Alexandre Gros	CEO & Non Independent Director	4.2yrs	US$2.55m	0.015% € 36.2k
Steven Perrin	President	4.2yrs	US$1.54m	0.0017% € 4.0k
Paul Little	Chief Financial Officer	3.7yrs	US$1.32m	0.017% € 40.2k
John Herberger	Vice President of Technical Operations	2.5yrs	データなし	データなし
Bryan Smith	General Counsel	3.6yrs	US$1.68m	0% € 0
David Hovland	Chief Regulatory Officer	3.6yrs	データなし	データなし
Eliezer Katz	Chief Medical Officer	1.1yrs	データなし	データなし

3.6yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: 2TKの経営陣は経験豊富であると考えられます ( 3.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
David-Alexandre Gros	CEO & Non Independent Director	4.2yrs	US$2.55m	0.015% € 36.2k
Steven Perrin	President	4.2yrs	US$1.54m	0.0017% € 4.0k
Keith Katkin	Independent Chairman of the Board	7.5yrs	US$1.52m	0.0011% € 2.7k
John McBride	Independent Director	7.5yrs	US$371.82k	0% € 0
James Robinson	Independent Director	1.1yrs	US$201.79k	データなし
June Lee	Independent Director	3.9yrs	US$374.44k	0% € 0
Hamid Djalilian	Member of Scientific Advisory Board	5.9yrs	データなし	データなし
Paola Marchisio	Member of Scientific Advisory Board	5.9yrs	データなし	データなし
Tal Marom	Member of Scientific Advisory Board	5.9yrs	データなし	データなし
Michael Pichichero	Member of Scientific Advisory Board	5.9yrs	データなし	データなし
Anne Schilder	Member of Scientific Advisory Board	5.9yrs	データなし	データなし
Seth Pranksy	Member of Scientific Advisory Board	5.9yrs	データなし	データなし

5.9yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: 2TKの取締役会は経験豊富であると考えられます ( 5.9年の平均在任期間)。

Eledon Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Chief Financial Officer recently bought €73k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought €73k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: €10.50

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

New 90-day low: €12.50

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

New 90-day high: €21.50

Novus Therapeutics, Inc. announced that it has received $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. announced that it expects to receive $108.15 million in funding from a group of investors

New 90-day high - €0.89

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

New 90-day low - €0.31

New 90-day low - €0.35

Novus Therapeutics, Inc.(NasdaqCM:NVUS) dropped from Russell Microcap Value Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24